Quantcast
Last updated on April 24, 2014 at 17:35 EDT

Latest Tetrabenazine Stories

2014-02-19 08:30:37

-- PDE10 Inhibitor Administered to Patients with Huntington's Disease -- SEATTLE, Feb. 19, 2014 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced dosing of the first patient in a second Phase 2 clinical trial of OMS824, the company's phosphodiesterase 10 (PDE10) inhibitor being developed for the treatment of schizophrenia, Huntington's disease (HD) and other cognitive disorders. The Phase 2 trial will evaluate the tolerability, safety, pharmacokinetics and performance...

2013-09-30 08:28:47

-- Phase 2 Clinical Trial in Huntington's Disease Slated to Begin This Year -- SEATTLE, Sept. 30, 2013 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) announced that OMS824, its phosphodiesterase 10 (PDE10) inhibitor, has received orphan drug designation from the U.S. Food and Drug Administration for the treatment of Huntington's disease. OMS824 selectively inhibits PDE10, an enzyme expressed in areas of the brain linked to a wide range of diseases that affect cognition, including...

2013-07-11 12:28:02

LA JOLLA, Calif., July 11, 2013 /PRNewswire/ -- Auspex Pharmaceuticals announced today that the first patient has been enrolled in a multi-center Phase 3 pivotal trial of its lead investigational drug, SD-809 for the treatment of involuntary movements (chorea) associated with Huntington's Disease (HD). Top-line data from the trial, designated the First-HD study, are expected in 2014. (Logo: http://photos.prnewswire.com/prnh/20130627/MM40068LOGO) "SD-809 is a deuterated...

2013-05-23 08:27:06

-- Clinical Trial in Patients with Huntington's Disease Slated to Begin Next Quarter -- SEATTLE, May 23, 2013 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced that its Investigational New Drug Application (IND) to evaluate OMS824 in Huntington's disease has been cleared by the U.S. Food and Drug Administration (FDA). OMS824 selectively inhibits phosphodiesterase 10 (PDE10), an enzyme expressed in areas of the brain linked to a wide range of diseases that affect...

2011-11-11 06:50:33

(Ivanhoe Newswire) -- No drug has been shown to improve the loss of the ability to move muscles voluntarily, until now. A new drug called pridopidine stabilizes dopamine signaling in areas of the brain that control movement and coordination. The findings were published online in the November 7 issue of The Lancet Neurology. "Pridopidine has the potential to complement available treatments by improving a different range of motor deficits," study authors were quoted as saying....

2010-03-05 12:33:00

Results achieved over 80 weeks of treatment consistent with statistically significant reduction in chorea demonstrated in pivotal study Lundbeck Inc. today announced the presentation of results from an open-label extension study of Xenazine® (tetrabenazine) for the treatment of chorea associated with Huntington's disease (HD). Data from this study demonstrated that after an 80-week treatment period, subjects treated with Xenazine experienced a statistically significant...

2009-10-06 15:45:00

NEW YORK, Oct. 6 /PRNewswire/ -- The Huntington's Disease Society of America (HDSA), will recognize the outstanding contributions to improving the quality of life of people with Huntington's Disease (HD) by several individuals and two organizations at the 13th annual Guthrie Awards Dinner this Thursday. All proceeds from the event go to the Woody and Marjorie Guthrie Research Fund, which has raised over $1,500,000 through this event. These funds help support the innovative HDSA...

2009-01-13 13:01:00

DURHAM, N.C., Jan. 13 /PRNewswire/ -- S&R Communications Group has entered a strategic partnership with Ovation Pharmaceuticals, Inc., to launch Xenazine* (tetrabenazine), a treatment for chorea associated with Huntington's disease (HD). Xenazine is the first and only FDA-approved treatment specifically developed for any HD-related symptom. "In recent months, the S&R team worked tirelessly to help Ovation launch Xenazine," said S&R President Paul Dreyer. "Having been...

2008-12-08 01:00:00

DUBLIN and NEWCASTLE, England, December 8 /PRNewswire/ -- - Marketing Partner UCB Expects to Receive Completed Price and Reimbursement Approval for Tetrabenazine in H1 2009 - Exclusive Distribution Rights Granted in Finland (MediFront) and Taiwan (Giddi Pharma); Distribution Contracts Renewed in Australia and New Zealand Cambridge Laboratories Limited ("Cambridge" or "the Company"), the privately-owned specialty pharmaceutical company, today announces that its flagship...

2008-10-28 06:00:28

By Rita Rubin Baylor College of Medicine neurologist Joseph Jankovic is a patient man. With the Food and Drug Administration's OK, Jankovic has studied the drug tetrabenazine since 1979. Over the years, he estimates, he has dispensed tetrabenazine -- or TBZ, as he calls it -- to 1,000 people with Huntington's disease, probably more than any doctor in the world. Tetrabenazine helps tame the uncontrollable movements, or "chorea," that characterize Huntington's, an inherited...